Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
复制标题
DOI：
10.1097/01.coc.0000195086.47548.ef
复制
发表时间：
2006-02-01
影响因子：
2.6
通讯作者：
Madani, A
中科院分区：
文献类型：
--
作者：
Einhorn, LH;Brames, MJ;Madani, A
目的：本II期研究旨在确定伊马替尼（格列卫）在kit阳性转移性生殖细胞肿瘤重度预处理患者中的活性。材料与方法：自2002年6月至2005年4月，对18例难治性生殖细胞肿瘤患者进行了KIT的免疫组化检测。所有接受筛查的患者都被认为是无法治愈的，需要进一步的标准化疗或手术。6例患者接受伊马替尼600 mg/d口服治疗。结果：无完全或部分缓解。6例患者中有5例病情进展，1例病情稳定，3个月后血清甲胎蛋白下降50%。结论：在这个小样本量中，没有证据表明伊马替尼对kit阳性的难治性生殖细胞肿瘤患者有显著的抗肿瘤活性。
Objective: This phase II study was conducted to determine the activity of imatinib (gleevec) in heavily pretreated patients with KIT-positive metastatic germ cell tumor.Materials and Methods: From June 2002 through April 2005, 18 patients with refractory germ cell tumors were tested for KIT expression by immunohistochemistry. All patients screened were deemed to be incurable with further standard chemotherapy or surgery. Six patients were eligible and treated with imatinib 600 mg/d orally.Results: There were no complete or partial remissions. Five of 6 patients had progressive disease and 1 patient had stable disease with a > 50% decline in serum alpha-fetoprotein for 3 months before developing further progression.Conclusion: In this small sample size, there was no evidence of significant antitumor activity of imatinib in patients with KIT-positive refractory germ cell tumors.